OCGN Company Profile and Key Details

Q: Who are the executives of OCGN?

Mr. Quan Anh VuChief Operating Officer & Chief Bus. OfficerDr. Arun Upadhyay Ph.D.Chief Scientific Officer and Head of Research, Devel. & MedicalJyothy PillaiHead of Regulatory & QualityMs. Jessica Crespo C.P.A., CPAChief Accounting Officer, Senior Vice President of Fin. and VP of Corporation Controller & TreasurerDr. Shankar Musunuri M.B.A., MBA, Ph.D.Co-Founder, Chairman & Chief Executive OfficerDr. Uday B. Kompella Ph.D.Co-founder & Independent DirectorMr. Michael Shine M.B.A.Senior Vice President of CommercialDr. Vijay Tammara Ph.D.Senior Vice President of Regulatory & QualityDr. Robert J. Hopkins FACP, M.D., M.P.H.Chief Medical OfficerMs. Tiffany Hamilton M.B.A.Head of Corporation CommunicationsMr. Michael ShineSenior Vice President of CommercialMs. Tiffany J. Hamilton M.B.A.Head of Corporation CommunicationsMs. Zara GaudiosoAVice President, Head of HR & Chief of StaffMs. Jessica Crespo CPA, CPAChief Accounting Officer, Senior Vice President of Fin. and VP of Corporation Controller & TreasurerMs. Jyothy Pillai M.S.Head of Regulatory & QualityDr. Huma Qamar CMI, M.D., M.P.H.Head of Clinical Devel. & Medical Affairs

NASDAQ : OCGN

Ocugen

$1.36

0.01+0.74%

At Close 4:00 PM

66.82

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Ocugen, Inc. (OCGN) stock surged +0.74%, trading at $1.36 on NASDAQ, up from the previous close of $1.35. The stock opened at $1.32, fluctuating between $1.31 and $1.38 in the recent session.

Stock Snapshot

1.35

Prev. Close

461.19M

Market Cap

1.31

Day Low

-5.23

P/E Ratio

-0.26

EPS (TTM)

-0.28

Cash Flow per Share

1.32

Open

339.11M

Number of Shares

1.38

Day High

92.2%

Free Float in %

0.16

Book Value

3.55M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 04, 2026	1.32	1.38	1.31	1.36	3.56M
Sep 03, 2026	1.34	1.35	1.30	1.35	2.41M
Sep 02, 2026	1.34	1.38	1.31	1.32	4.27M
Sep 01, 2026	1.33	1.34	1.29	1.33	2.17M
Aug 31, 2026	1.32	1.34	1.28	1.33	4.65M
Aug 28, 2026	1.37	1.37	1.32	1.32	3.05M
Aug 27, 2026	1.42	1.42	1.36	1.37	2.89M
Aug 26, 2026	1.41	1.42	1.38	1.41	1.99M
Aug 25, 2026	1.39	1.43	1.38	1.40	4.59M
Aug 24, 2026	1.41	1.41	1.33	1.36	2.88M
Aug 21, 2026	1.41	1.42	1.37	1.39	2.43M
Aug 20, 2026	1.45	1.46	1.38	1.39	3.95M
Aug 19, 2026	1.38	1.49	1.35	1.48	6.84M
Aug 18, 2026	1.38	1.38	1.32	1.34	2.52M
Aug 17, 2026	1.34	1.38	1.32	1.38	2.49M
Aug 14, 2026	1.36	1.36	1.31	1.35	2.97M
Aug 13, 2026	1.41	1.44	1.34	1.35	3.9M
Aug 12, 2026	1.37	1.42	1.37	1.40	3.17M
Aug 11, 2026	1.32	1.37	1.30	1.37	2.46M
Aug 10, 2026	1.27	1.32	1.26	1.31	3.77M

Contact Details

Malvern, PA 19355

United States

https://www.ocugen.com 484 328 4701

About Company

Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.

Stock Peers

ARGX

-20.31-1.93%

argenx SE$1,033.15 REGN

-15.75-1.87%

Regeneron Pharmaceuticals, Inc.$827.72 VRTX

-11.84-2.12%

Vertex Pharmaceuticals Incorporated$546.12 MDGL

-1.53-0.28%

Madrigal Pharmaceuticals, Inc.$541.08 UTHR

-2.63-0.54%

United Therapeutics Corporation$487.61 ONC

-4.42-1.22%

BeOne Medicines AG$358.26 KRYS

-13.23-3.56%

Krystal Biotech, Inc.$358.24 PRAX

-3.34-0.94%

Praxis Precision Medicines, Inc.$351.81 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

-4.14-1.43%

Ligand Pharmaceuticals Incorporated$285.60

Frequently Asked Questions

What is the current Ocugen, Inc. (OCGN) stock price?

Ocugen, Inc. (NASDAQ: OCGN) stock price is $1.36 in the last trading session. During the trading session, OCGN stock reached the peak price of $1.38 while $1.31 was the lowest point it dropped to. The percentage change in OCGN stock occurred in the recent session was 0.74% while the dollar amount for the price change in OCGN stock was $0.01.

OCGN's industry and sector of operation?

The NASDAQ listed OCGN is part of Biotechnology industry that operates in the broader Healthcare sector. Ocugen, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of OCGN?

Mr. Quan Anh Vu
Chief Operating Officer & Chief Bus. Officer
Dr. Arun Upadhyay Ph.D.
Chief Scientific Officer and Head of Research, Devel. & Medical
Jyothy Pillai
Head of Regulatory & Quality
Ms. Jessica Crespo C.P.A., CPA
Chief Accounting Officer, Senior Vice President of Fin. and VP of Corporation Controller & Treasurer
Dr. Shankar Musunuri M.B.A., MBA, Ph.D.
Co-Founder, Chairman & Chief Executive Officer
Dr. Uday B. Kompella Ph.D.
Co-founder & Independent Director
Mr. Michael Shine M.B.A.
Senior Vice President of Commercial
Dr. Vijay Tammara Ph.D.
Senior Vice President of Regulatory & Quality
Dr. Robert J. Hopkins FACP, M.D., M.P.H.
Chief Medical Officer
Ms. Tiffany Hamilton M.B.A.
Head of Corporation Communications
Mr. Michael Shine
Senior Vice President of Commercial
Ms. Tiffany J. Hamilton M.B.A.
Head of Corporation Communications
Ms. Zara Gaudioso
AVice President, Head of HR & Chief of Staff
Ms. Jessica Crespo CPA, CPA
Chief Accounting Officer, Senior Vice President of Fin. and VP of Corporation Controller & Treasurer
Ms. Jyothy Pillai M.S.
Head of Regulatory & Quality
Dr. Huma Qamar CMI, M.D., M.P.H.
Head of Clinical Devel. & Medical Affairs

How OCGN did perform over past 52-week?

OCGN's closing price is 34.65% higher than its 52-week low of $1.01 where as its distance from 52-week high of $2.73 is -50.09%.

How many employees does OCGN have?

Number of OCGN employees currently stands at 116.

Link for OCGN official website?

Official Website of OCGN is: https://www.ocugen.com

How do I contact OCGN?

OCGN could be contacted at phone 484 328 4701 and can also be accessed through its website. OCGN operates from 263 Great Valley Parkway, Malvern, PA 19355, United States.

How many shares of OCGN are traded daily?

OCGN stock volume for the day was 3.55M shares. The average number of OCGN shares traded daily for last 3 months was 6.09M.

What is the market cap of OCGN currently?

The market value of OCGN currently stands at $461.19M with its latest stock price at $1.36 and 339.11M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	116
Beta	2.2
Sales or Revenue	$6.04M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	116
Beta	2.2
Sales or Revenue	$6.04M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

OCGN Company Profile and Key Details

Ocugen

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook